Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chantix Meta-Analyses Not Enough To Remove Boxed Warning, FDA Argues

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer wants advisory committee to endorse several labeling changes for its smoking cessation drug, but FDA says decision should wait for post-marketing trial set to be completed in about a year.

You may also be interested in...



FDA’s Black Box Instant Replay: A Higher Standard To Remove

Pfizer’s request for leniency on Chantix will likely be shelved, but advisory committee allows exploration of regulatory area where FDA has limited experience: The rollback of safety labeling.

Pfizer’s Effort To Remove Chantix Boxed Warning May Backfire

Most FDA advisory committee members vote to wait until clinical trial results are submitted, but some also say warning should be include additional adverse events.

Chantix Faces FDA Safety Gauntlet After Pfizer Settles Product Liability Suits

FDA advisory committees will discuss risk of serious neuropsychiatric adverse events with the smoking cessation drug at October meeting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel